Drug Indication Expansion: Unlocking Untapped Potential
In the vast ecosystem of the pharmaceutical industry, drug indication expansion plays a pivotal role in maximizing the potential of existing drugs. This critical aspect of health and medicine enables companies to provide more treatments for patients, while potentially increasing revenue. What is Drug Indication Expansion? Drug indication expansion refers to the approval of existing […]
Advancing Healthcare Through Drug Discovery Services: Unleashing the Power of Innovation
In the realm of healthcare, the journey from a promising drug idea to an effective therapy is not a straightforward one. The process of drug discovery is highly complex and generally takes years from the initial idea to – in an ideal scenario – the final approval. It requires experts from different fields, therefore making […]
What is Drug Discovery? Unveiling the Process, Challenges, and Future
In the intricate world of healthcare, the journey of a drug from a basic idea to a therapy that can change lives is a challenging one. This process, known as drug discovery, is a rigorous, meticulous, and elaborate journey that requires a high level of expertise in various fields such as biology, chemistry, computer science, […]
Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform
Delta4, a digital drug discovery company, identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS) using their Hyper-C AI software platform. The anti-platelet drug clopidogrel was among the top predictions and was shown to alleviate disease progression in an accepted FSGS animal model, suggesting it is a promising candidate for clinical trials. May 24, […]
Understanding the Drug Discovery Pipeline: From the Lab to the Patient
The world of pharmaceuticals is complex and layered. At the heart of this realm is the drug discovery pipeline, a multi-stage process that transforms scientific concepts into life-saving therapies. We’re going to explore the journey that a drug takes from the initial discovery or identification to clinical trials and ultimately into the hands of patients. […]
The Transformative Role of AI in Pharma – An Exploration
What is Artificial Intelligence? Artificial Intelligence (AI) is a field of computer science that aims to mimic human intelligence, enabling machines to learn from experience, adjust to new inputs, and perform tasks that normally require human intelligence. It’s a broad term encompassing various technologies, including machine learning, natural language processing, and vision technologies. AI’s impact […]
Delta4 CEO Kurt Herpel Featured in Insightscare Magazine: A Vision for the Future of Drug Discovery
We are incredibly proud to share that our esteemed CEO, Kurt Herpel, has recently been profiled in Insightscare Magazine. In the article titled “Kurt Herpel: Revolutionizing Drug Discovery Through Artificial Intelligence,” Kurt shares his vision for the future of drug discovery, highlighting the transformative potential of artificial intelligence (AI) in advancing healthcare solutions. AI and […]
Delta4 Announces Prof. Doron Lancet To Join Scientific Advisory Board
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that Prof. Doron Lancet will join its Scientific Advisory Board. Prof. Lancet is a distinguished scientist in the area of genetics and systems biology. “We are excited to have Prof. […]
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no […]
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and genetic background. FSGS patients often progress to end-stage renal disease requiring dialysis and/or kidney transplantation, adding a significant socioeconomic burden to the individual burden of patients. There are approximately 140.000 patients with FSGS worldwide, qualifying […]